<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03541057</url>
  </required_header>
  <id_info>
    <org_study_id>VALID 1928/2017</org_study_id>
    <nct_id>NCT03541057</nct_id>
  </id_info>
  <brief_title>Vienna Vascular Liver Disease Study</brief_title>
  <acronym>VALID</acronym>
  <official_title>Vienna Vascular Liver Disease Study: Characterization of Patients With Vascular Liver Disease - a Registry With Biobank</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this Register Trial is to systematically study the epidemiology, risk factors,
      liver function as well prognosis of patients with vascular liver diseases. Furthermore,
      important clinical parameters will be assessed in order to evaluate patients' coagulation
      status and in order to develop new biomarkers derived from blood, urine, stool or ascites of
      patients as well as histological samples from the upper / lower GI-tract or the liver in
      order to better understand the natural history of vascular liver diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will include patients with vascular liver diseases, including

        -  portal vein thrombosis (PVT)

        -  Budd-Chiari Syndrome (BCS)

        -  Heredetary Hemorrhagic Teleangiectasia (HHT, or Osler-Rendu Disease)

        -  Noncirrhotic-portal hypertension (NCPH)

        -  Cirrhosis cardiaque if the fulfill inclusion/exclusion criteria and provide written
           informed consent. Participation in the biobank is optional for the patients. In
           particular, we will study the natural course of the patients in regard to hepatic
           decompensation (ascites, variceal bleeding, hepatic encephalopathy), need for
           intensified treatment (TIPS, ICU, liver transplantation) and survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Hepatic Decompensation</measure>
    <time_frame>Up to 10 years (=Study Period)</time_frame>
    <description>Any first hepatic decompensation: variceal bleeding, new onset of ascites, new onset of hepatic encephalopathy, new onset of jaundice</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver-related death</measure>
    <time_frame>Up to 10 years (=Study Period)</time_frame>
    <description>Death from a liver-related cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation status</measure>
    <time_frame>Up to 10 years (=Study Period)</time_frame>
    <description>Coagulation status of the Patient as assessed by advanced coagulation tests (including TEG-ROTEM and TGA)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Vascular Liver Disease</condition>
  <condition>Portal Vein Thrombosis</condition>
  <condition>Budd-Chiari Syndrome</condition>
  <condition>Non-Cirrhotic Portal Hypertension</condition>
  <condition>Rendu Osler Weber</condition>
  <condition>Cardiac Cirrhosis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, stool, urine, liver tissue, tissue from the lower / upper gastrointestinal tract
      (biopsy)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients with a vascular liver disease (as specified above) presenting at
        the outpatient department / inpatient ward of the Medical University of Vienna.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a vascular liver disease by imaging (sonography, CT, MRI), transient
             elastography or liver histology

          -  PVT: Portal vein thrombosis

          -  NCPH: non-cirrhotic Portal Hypertension

          -  BCS: Budd-Chiari-Syndrome

          -  SOS: sinusoidal occlusive disease

          -  HHT: hereditary hemorrhagic teleangiectasia

          -  CIRCAD: cirrhosis cardiaque

          -  Age &gt;18 years and &lt;100 years

          -  Written informed consent obtained

        Exclusion Criteria:

        - withdrawal of written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Reiberger, MD</last_name>
    <phone>0043140400</phone>
    <phone_ext>47410</phone_ext>
    <email>thomas.reiberger@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bernhard Scheiner, MD</last_name>
    <phone>0043140400</phone>
    <phone_ext>47410</phone_ext>
    <email>bernhard.scheiner@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Reiberger, MD</last_name>
      <phone>0043140400</phone>
      <phone_ext>47410</phone_ext>
      <email>thomas.reiberger@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Bernhard Scheiner, MD</last_name>
      <phone>0043140400</phone>
      <phone_ext>47410</phone_ext>
      <email>bernhard.scheiner@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Reiberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernhard Scheiner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mattias Mandorfer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Schwabl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theresa Bucsics, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katharina Lampichler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Pinter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 6, 2018</study_first_submitted>
  <study_first_submitted_qc>May 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>August 16, 2019</last_update_submitted>
  <last_update_submitted_qc>August 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Thomas Reiberger</investigator_full_name>
    <investigator_title>Assoc.-Prof. Priv.-Doz. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Budd-Chiari Syndrome</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

